Mesothelioma is an insidious disease, silently taking over the sufferer and often not showing symptoms until the disease is so far progressed that little can be done in terms of treatment. This makes the survival rate of mesothelioma very low, with only around half of those diagnosed living for more than a year after diagnosis. Sadly, we hear all too often from families who have lost their loved ones only a matter of weeks after diagnosis.
There is, unfortunately, still no cure for mesothelioma but each year the treatments available are improving and for those who are diagnosed early on, prospects are much better. Early detection is the key to giving mesothelioma patients more time and a better quality of life.
New research, presented at the 17th World Conference on Lung Cancer in Vienna in December last year, gives hope for an early mesothelioma diagnosis. They have identified a new biomarker, Fibroblast Growth Factor 18 (FGF18), which can help to show if mesothelioma is present.
Biomarkers are substances in the bloodstream that can signal the presence of a certain disease. While biomarkers have been used for some time to help with the diagnosis of mesothelioma, the results of this study have shown that FGF18 may be a better indicator of mesothelioma than others.
Although the results of this study are promising, the test for FGF18 is still at the clinical trial stage and it may be sometime before this test can be used.
Here at Asbestos Justice we are pleased that research is continuing into the diagnosis and treatment of mesothelioma. Any medical advancements that can help those who develop this horrendous disease are welcomed.
If you require assistance in pursuing an asbestos compensation claim for mesothelioma or other asbestos disease then please contact us today on our freephone number 0800 038 6767. Alternatively, head over to the ‘Contact Us’ page, complete the form and we will be in touch.
Source: M. Grusch. Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients – A Multi-Institutional Study.